tbuckley/cabot-search huggingface dataset:
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary results.
Authors: S. F. Slovin, M. Kargman, R. Durso, T. Curley, R. J. Israel, W. C. Olson, S. Morris, D. Murphy, H. I. Scher
Journal: Journal of Clinical Oncology (2011)

140 Background: Prostate-specific membrane antigen (PSMA), a type II transmembrane protein overexpressed in prostate cells as they emerge into the androgen-independent state, remains a target to which vaccines with novel adjuvants or naked DNA has been directed. The PSMA-Viral Replicon Package (VRP) is a propagation-defective vector system from an attentuated strain of an alpha virus (VEE) encoding PSMA for use as a vaccine in prostate cancer. The PSMA gene is encoded by a subgenomic messenger RNA (mRNA), leading to high level expression of PSMA protein and presentation to the immune system.. We report preliminary results of a first in human trial using PSMA VRP to elicit immune responses targeting PSMA. Methods: Up to 18 pts with chemotherapy naïve CRPC metastatic to bone or soft tissue were permitted with 12 pts enrolled with ECOG status of 0 or 1. PSMA VRP was administered SC doses of either 0.9×10 7 IU or 0.36×10 8 IU for a total of 5 doses given on weeks 1, 4, 7, 10 and 18. Adverse events, PSA, circulating tumor cells, and clinical disease progression were assessed. Immune assessment was performed on patients' sera by ELISA and flow cytometry of serum binding to PSMA expressing tumor cells (3T3) and cellular (IFN-g EliSpot) components. Patients underwent imaging with bone and CAT scans every 3 months. Results: Three pts received 0.9×10 7 IU and 9 received 0.36×10 8 IU. Of these, 8 pts received all 5 vaccines. Four pts were taken off study for disease progression. One pt at the 0.36×10 8 continues on study and will be receiving his seventh vaccine. The demographic featuresof the 12 subjects enrolled were similar (mean age 69±11 yrs). No significant adverse events were noted; no aberrant laboratory abnormalities were associated with treatment. Weak humoral responses were observed in 1 patient in the 0.9×10 7 IU group and in 3 treated at 0.36×10 8 . Conclusions: In this first-in-man evaluation, vaccination with PSMA VRP appeared to be well-tolerated but does not appear to show impact on disease progression. Further studies are ongoing to assess immune responses and identify potential pathways for enhancement of the PSMA VRP approach. [Table: see text]
Use of zoledronic acid therapy–associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer.
Authors: Julia Warr, David Yam, Shannon Goodall, Leah VanDraanen, Angie Giotis, Mark Pasetka, Carlo De Angelis, Urban Emmenegger
Journal: Journal of Clinical Oncology (2012)

58 Background: Zoledronic acid (ZOL) therapy is associated with severe (i.e., grade 3/4 according to CTCAEv4.0) hypocalcemia and hypophosphatemia in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) to bone. However, as opposed to the distinct clinical picture of hypocalcemia, the symptoms of hypophosphatemia are less pathognomonic. Furthermore, the rate of hypophosphatemia is not regularly reported. Methods: To characterize the rate and circumstances of severe hypophosphatemia in mCRPC patients undergoing ZOL therapy, we identified mCRPC patients receiving at least 3 doses of ZOL therapy at our Centre between 2004 and 03/2011. Patient demographics, disease and laboratory parameters were extracted by using the Oncology Symptom Control and Information Resource database, and by means of manual chart review. Results: 11 of 112 patients (10%) developed grade 3/4 hypophosphatemia (nadir) after 241±223 days (mean±SD) following the first dose of ZOL. Only one patient presented with concomitant severe hypocalcemia. Interestingly, the hypophosphatemia nadir coincided with rising PSA readings in 9 out of 10 informative patients. Furthermore, ZOL-associated severe hypophosphatemia identified mCRPC patients with worse outcome (time from CRPC diagnosis to death 628±317 days, versus 901±526 days in CRPC patients without severe ZOL-associated hypophosphatemia, p &lt; 0.028). Conclusions: 10% of mCRPC patients undergoing ZOL therapy presented with grade 3/4 hypophosphatemia. While hypocalcemia usually occurs within the first 6 months of ZOL therapy, ZOL-associated severe hypophosphatemia is a relatively late event. It appears to occur at the time of disease progression and is associated with a poor outcome.
Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation.
Authors: Rentian Feng, Huihui Ma, Noriyoshi Kurihara, Shirong Li, Judy A Ziegler, Markus Y Mapara, G. David Roodman, Suzanne Lentzsch
Journal: Blood (2009)
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Authors: S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. R. C. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton
Journal: Journal of Clinical Oncology (2011)

CRA9015 Background: Hot flashes are a common symptom during the menopause transition or following breast cancer treatment that can negatively impact the quality of life for many women. Preliminary data have suggested that flaxseed, a rich source of dietary lignans, may be a potentially effective treatment for hot flashes. Methods: A phase III randomized, placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes. Postmenopausal women were randomly assigned to a flaxseed bar (providing 410 mg of lignans) for 6 weeks vs a placebo bar. Participants completed daily prospective, self report hot flash diaries during the baseline week and then began eating one study bar per day for 6 weeks, while continuing to record their daily hot flashes. The intra-patient difference in hot flash activity between baseline and the last treatment week was the primary endpoint. Side effects of the bars were evaluated through self report and CTC assessment. Results: Between October and December 2009, 188 women were enrolled onto this trial. Mean hot flash scores were reduced by 4.9 units in the flaxseed group and 3.5 in the placebo group (p=0.29). In both groups, a little over a third of the women received a 50% reduction in their hot flash scores. Only one side effect was significantly different between groups, that being grade 1 pruritis, which was more common (7%) in the placebo group versus 1% in the flaxseed group. Both groups reported increased abdominal distension, flatulence, diarrhea and nausea. Adherence and ability to detect treatment assignment did not differ between groups. Conclusions: The results of this trial do not support the use of 410 mg of flaxseed lignans for the reduction of hot flashes. The gastrointestinal side effects seen in both groups were likely due to the fiber content in the flaxseed and placebo bars.
Use of a MET-specific photoprobe to identify bladder tumors in an orthotopic xenograft model of bladder cancer.
Authors: M. Sorbellini, A. Giubellino, G. Srivastava, C. Sourbier, E. Jagoda, M. Williams, P. L. Choyke, P. A. Pinto, W. Linehan, D. P. Bottaro
Journal: Journal of Clinical Oncology (2011)

260 Background: Met over-expression has been found in bladder cancer (CaB). Stage and grade increases in urothelial carcinoma have been found to correlate with increases in Met expression. To assess whether molecular optical imaging could enhance the detection of bladder tumors, we used a Met-specific soluble photoprobe in an orthotopic xenograft model of bladder transitional cell carcinoma (TCC). Methods: An orthotopic xenograft murine model of CaB was developed with T24-Luciferase-positive bladder cancer cells. Presence of tumor was confirmed by luciferase optical imaging (Xenogen IVIS) of mice, 4 weeks after TCC cell implantation. Mice were euthanized and their bladders removed and bivalved. Bladders were incubated for 30 minutes with unbound fluorophore (Cy5**, Peak emission at 675 nM) and subsequently for another 30 minutes with Cy5** bound to a Met-specific peptide. Fluorescence imaging (Maestro) was performed before and after each incubation period. Following imaging, presence of tumor was confirmed histologically. Results: Cy5**-Met- peptide bound in sufficient density to tumor tissue in bladders for visualization by optical imaging. The tumor to normal bladder imaging ratio ranged from 2:1 to 8:1. Bladder regions with high uptake of Cy5**-Met-peptide corresponded to tumor areas confirmed by histological analysis. Conclusions: Cy5**-Met-peptide successfully targets Met in an orthotopic xenograft model of bladder cancer. Our results suggest that this agent maybe useful for the enhanced visualization of bladder cancer tumors during cystoscopy. No significant financial relationships to disclose.
Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Nancy M. Hardy, Vicki Fellowes, Jeremy Rose, Daniel H. Fowler, Ronald E. Gress, Bruce L. Levine, Carl H. June, Frances T Hakim, Michael R. Bishop
Journal: Blood (2010)
Media Use and Sleep
Authors: Megan A. Moreno
Journal: JAMA Pediatrics (2016)

Ben Carter, PhD, MSc; Philippa Rees, MPhil, MBBCh; Lauren Hale, PhD, MPH; Darsharna Bhattacharjee, MBChB, MRCPCH; Mandar S. Paradkar, MBBS, DCH, MPH
Effect of open versus robot-assisted laparoscopic radical prostatectomy on cancer control in patients with clinically localized prostate cancer: Prospective analysis of 1,014 consecutive patients.
Authors: Adrian Stuart Fairey, Niels Jacobsen, Don Voaklander, Eric Estey
Journal: Journal of Clinical Oncology (2012)

80 Background: There are limited prospective data comparing outcomes of Open Radical Prostatectomy (ORP) and Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) for clinically localized prostate cancer. Our aim was to compare ORP and RALRP with respect to cancer control outcomes. Methods: A prospective analysis of data from the University of Alberta Radical Prostatectomy Database was performed. Between September 2007 and August 2010, 1019 consecutive men underwent radical prostatectomy for clinically localized prostate cancer. The surgical approach was selected by the surgeon. The outcomes were biochemical recurrence (BCR) and positive surgical margins (PSM). BCR was defined as a PSA ≥ 0.1 ng/ml followed by a subsequent confirmatory value or initiation of salvage therapy. PSM was defined as the presence of cancer at the inked margin in the radical prostatectomy specimen. The Kaplan-Meier method was used to estimate biochemical recurrence free survival (BCRFS). Univariable and multivariable analyses were used to determine the association between surgical approach and outcomes. Results: Data were evaluable for 1014 out of 1019 patients. 204 patients underwent ORP and 810 patients underwent RALRP. The median follow-up duration was 21 months (IQR 12 to 29). Baseline characteristics were similar between the groups. In univariable analysis, 3-year BCRFS (90.6% versus 88.9%), overall PSM (26.5% versus 28.8%), and stage-stratified PSM (pT2: 19.9% versus 21.8%; pT3: 40.6% versus 49.1%) did not differ between the groups (all comparisons p&gt;0.05). In multivariable analysis, surgical approach was not independently associated with BCR (HR 0.77, 95% CI 0.43 to 1.37, p=0.37) or PSM (OR 1.2, 95% CI 0.80 to 1.67, p=0.44). Conclusions: ORP and RALRP provided comparable short-term oncologic efficacy. Extended follow-up of the prospective cohort is needed to confirm these preliminary findings.
Progress in Epilepsy
Authors: Jonathan K. Kleen, Daniel H. Lowenstein
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C – Clonal complex 11 in the Florence province, Italy, 2015–2016
Authors: Francesco Maria Fusco, Filippo Baragli, Barbara Del Pin, Rosario Spina, Italo Calamai, Patrizia Pecile, Eleonora Riccobono, Francesco Nieddu, Maria Moriondo, Alessandro Miglietta, Fabio Voller, Cecilia Fazio, Paola Stefanelli, Massimo Di Pietro
Journal: Journal of Infection (2016)
Radiofrequency ablation versus hepatic resection as an initial treatment for solitary small-sized hepatocellular carcinoma.
Authors: Katsunori Imai, Toru Beppu, Akira Chikamoto, Koichi Doi,, Hirohisa Okabe, Hidetoshi Nitta, Hiromitsu Hayashi, Takatoshi Ishiko, Hiroshi Takamori, Hideo Baba
Journal: Journal of Clinical Oncology (2012)

290 Background: Nowadays Radiofrequency ablation (RFA) is a popular method and demonstrates favorable results for the treatment of small-sized hepatocellular carcinoma (HCC). However, whether RFA is as effective as hepatic resection (HR) for long-term outcomes remains controversial. The aim of this study is to compare HR and RFA with regard to survival and recurrence for the establishment of treatment strategy of small-sized HCC. Methods: A total of 183 patients with solitary small-sized (≤3cm) HCC were enrolled in this study: 101 patients underwent HR and 82 underwent RFA as an initial treatment. Overall survival (OS) and disease-free survival (DFS) were compared between the two groups and in subgroup analyses. Results: Patients who underwent RFA had less platelet count (HR: 15.3±7.0, RFA: 9.8±3.6, P&lt;0.01), and more advancer Child-Pugh class (A/B = HR: 97/4, RFA: 61/22, P&lt;0.01). The 5-year OS and DFS were significantly higher in the HR group compared with the RFA group (OS: 90% vs 59%, P&lt;0.01, DFS: 45% vs 27%, P&lt;0.01, respectively). In multivariate analyses, treatment modality (HR or RFA) and gender were indipendent predicting factors for DFS (RR: 1.85, P=0.05, and RR: 2.15, P=0.01, respectively). In subgroup analyses of HCC &lt;2cm, there was no significant difference in OS and DFS between the two group (5-year OS: 90% vs 74%, P=0.40, 5-year DFS: 43% vs 28%, P=0.24, respectively), despite the differences in liver functional reserve. However, HR was superior to RFA for OS and DFS in subgroup ≥2cm (5-year OS: 85% vs 32%, P&lt;0.01, 5-year DFS: 40% vs 23%, P&lt;0.01). In the subgroup analyses treated by RFA, GPT &gt;35mIU/ml and tumor ≥2cm were significant predicting factors for DFS (RR: 2.34, P=0.01, and RR: 2.09, P=0.02, respectively). For OS, tumor ≥2cm was the only prognostic factor (RR: 2.9, P=0.04). Conclusions: RFA might be as effective as HR for the treatment of solitary HCC &lt;2cm. However, in the patients with HCC ≥2cm, HR provides a better OS and DFS than RFA.
Utility of breast MRI for patients with breast-cancer scheduled for breast-conserving surgery.
Authors: H. Shin, W. Han, H. Moon, C. K. Yom, S. K. Ahn, H. Kim, D. Noh
Journal: Journal of Clinical Oncology (2011)

1086 Background: Purposes of this study is to compare the operation results between MRI group and none MRI group in breast cancer patients underwent BCS and to evaluate the accuracy of breast MRI for assessing tumor size. Methods: Between January 2003 and October 2005, 1610 consecutive patients who underwent breast cancer surgery were studied retrospectively. 750 patients received BCS and 486 patients (64.8%) of MRI group and 264 patients (35.2%) of non-MRI group were studied. To evaluate the accuracy of breast MRI, we compared pathologic tumor size with tumor size with breast MRI and sonography. Results: There was no significant difference of pT and N stage between MRI group and non-MRI group in patients received BCS (p=0.065). In MRI group vs. non-MRI group, margin was positive at frozen section in 36 patients (13.6%) vs. 97 (20.0%) with statistical significance (p=0.006). In non-MRI group, 12 patients (4.5%) underwent additional breast resection and none was converted to mastectomy. In MRI group, 70 patients (14.4%) had to resect breast additionally for margin positivity and 2 patients (0.4%) were converted to total mastectomy. Additional resection was performed in MRI group more than non-MRI group (p<0.0001). Local recurrence rate after BCS was not different between MRI group (5.8%) and non-MRI group (5.3%)(p=0.766). 5-year LRFSR was not different between MRI group (94.4%) and non-MRI group (94.6%) (p=0.837). However, 5-year OSR of MRI group was 94.1%, rate of non-MRI group was 90.1% (p=0.044). Tumor size of invasive component and size on MRI was significantly different (p<0.0001), but there was no significant difference between tumor size of invasive component and size on breast sonography (p=0.717). However, tumor size including DCIS component and size on MRI was not different (p=0.548), but tumor size including DCIS component and size on sonography was significantly different (p<0.0001). Conclusions:Margin positivity and additional resection rate was higher in MRI group. OSR was slightly higher in MRI group than in non-MRI group. Breast sonography was more accurate for measuring invasive component than breast MRI, but MRI exhibited more accurate for measuring tumor size including DCIS component.
Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.
Authors: Girindra G Raval, Morie A Gertz, Martha Q Lacy, Suzanne R Hayman, Shaji K. Kumar, Francis K Buadi, John A. Lust, Steven Zeldenrust, David Dingli, Robert L Hall, Lisa Hwa, Yi Lin, Prashant Kapoor, Thomas E. Witzig, Robert A. Kyle, Stephen Russell, Nelson Leung, S. Vincent Rajkumar, Angela Dispenzieri
Journal: Blood (2012)
Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.
Authors: Pier Paolo Piccaluga, Philip Went, Claudio Agostinelli, Andrea Gallamini, Stefano Ascani, Elena Sabattini, Francesco Bacci, Brunangelo Falini, Teresio Motta, Marco Paulli, Tullio Artusi, Pier Luigi Zinzani, Michele Baccarani, Stefano A. Pileri
Journal: Blood (2005)
Medical Schools in the United States, 2008-2009
Authors: Barbara Barzansky, Sylvia I Etzel
Journal: JAMA (2009)

THE FOLLOWING TABLES CONtain data derived mainly from the 2008-2009 Liaison Committee on Medical Education (LCME) Annual Medical School Questionnaire. The questionnaire was sent in February 2009 to the deans of all 126 LCME-accredited medical schools with enrolled students and had a 100% response rate. Each questionnaire was reviewed and attempts were made to verify information and obtain missing data. Data for years other than 20082009 were obtained from previous LCME Annual Medical School Questionnaires and other sources, as indicated.
Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer.
Authors: S. A. Carp, C. Wanyo, M. Specht, L. Schapira, B. Moy, D. Finkelstein, D. Boas, S. J. Isakoff
Journal: Journal of Clinical Oncology (2011)

10607 Background: Recent studies using near-infrared optical measurements in breast tumors have demonstrated the promise of early monitoring of neoadjuvant chemotherapy (NAC) to predict outcome. Technologies to date have focused primarily on static measurements. Dynamic optical imaging, in conjunction with fractional mammographic compression, offers access to multiple functional and metabolic tissue biomarkers that may be used to predict treatment response. We have developed a novel tomographic optical breast imaging (TOBI) device to evaluate the early (day 7) prediction performance of this advanced technology. Methods: We are conducting a pilot feasibility study in female patients with unilateral locally advanced breast cancer undergoing standard-of-care NAC. Pre-treatment and day 7 post-treatment TOBI scans are obtained, with additional scans on day 1 of each subsequent chemotherapy cycle. The affected and contralateral normal breasts are compressed to 6-8 lbs of force and optical images are acquired once every 2 seconds for two minutes. Time-resolved oxy-(HbO), deoxy-(HbR), and total-(HbT) hemoglobin concentration and hemoglobin oxygen saturation (SO2) are calculated. The compression-induced rate of change of HbT correlates with changes in tissue blood volume indicative of biomechanical properties and the evolution of tissue SO2 estimates tissue metabolism. Results: We report initial data from two patients. One patient had a near-pathologic complete response (responder) and showed 21% and 23% decreases in HbT and HbR, respectively. The second patient had no significant response (non-responder) and had 2% and 1% decreases in HbT and HbR, respectively. Interestingly, the responder showed a dynamic decrease in HbT during compression in the tumor region at day 0 that disappeared at day 7, while the non-responder had similar rates of HbT change at both scans. Conclusions: We demonstrate for the first time the feasibility of dynamic optical breast tomography and show that optically derived parameters may be sensitive to therapy-induced changes in breast cancer. These dynamic measurements may provide novel insight into the physiologic changes in breast tumors during treatment.
Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma
Authors: Julien Dubreuil, Robin Noel, Jeremie Tordo, Gilles Salles, Andrea Skanjeti
Journal: Clinical Nuclear Medicine (2016)

Marginal zone lymphoma (MZL) is usually considered not avid for FDG. We report a case of a 57-year-old man with an MZL suspected for transformation. FDG-PET/CT showed a diffuse atypical involvement of subcutaneous fat, without sign suggestive for a transformation. No cutaneous involvement was clinically evident. A random subcutaneous biopsy was performed and showed the presence of MZL.